JP6779232B2 - ウイルス感染の治療又は予防のための新規オキサチオランカルボン酸と誘導体 - Google Patents

ウイルス感染の治療又は予防のための新規オキサチオランカルボン酸と誘導体 Download PDF

Info

Publication number
JP6779232B2
JP6779232B2 JP2017558025A JP2017558025A JP6779232B2 JP 6779232 B2 JP6779232 B2 JP 6779232B2 JP 2017558025 A JP2017558025 A JP 2017558025A JP 2017558025 A JP2017558025 A JP 2017558025A JP 6779232 B2 JP6779232 B2 JP 6779232B2
Authority
JP
Japan
Prior art keywords
thiazolo
amino
pyrimidin
compound
dioxo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2017558025A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018515503A5 (OSRAM
JP2018515503A (ja
Inventor
リウ，ハイシア
ウー，グオローン
ユイン，ホーンイーン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of JP2018515503A publication Critical patent/JP2018515503A/ja
Publication of JP2018515503A5 publication Critical patent/JP2018515503A5/ja
Application granted granted Critical
Publication of JP6779232B2 publication Critical patent/JP6779232B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2017558025A 2015-05-08 2016-05-04 ウイルス感染の治療又は予防のための新規オキサチオランカルボン酸と誘導体 Expired - Fee Related JP6779232B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2015078578 2015-05-08
CNPCT/CN2015/078578 2015-05-08
PCT/EP2016/059949 WO2016180691A1 (en) 2015-05-08 2016-05-04 Novel oxathiolane carboxylic acids and derivatives for the treatment and prophylaxis of virus infection

Publications (3)

Publication Number Publication Date
JP2018515503A JP2018515503A (ja) 2018-06-14
JP2018515503A5 JP2018515503A5 (OSRAM) 2019-06-06
JP6779232B2 true JP6779232B2 (ja) 2020-11-04

Family

ID=55910268

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017558025A Expired - Fee Related JP6779232B2 (ja) 2015-05-08 2016-05-04 ウイルス感染の治療又は予防のための新規オキサチオランカルボン酸と誘導体

Country Status (5)

Country Link
US (1) US10183954B2 (OSRAM)
EP (1) EP3294745B1 (OSRAM)
JP (1) JP6779232B2 (OSRAM)
CN (1) CN107743491B (OSRAM)
WO (1) WO2016180691A1 (OSRAM)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7287708B2 (ja) 2019-02-08 2023-06-06 プロジェニア インコーポレイテッド Ｔｏｌｌ－ｌｉｋｅ受容体７または８アゴニストとコレステロールの結合体およびその用途
JP2023516372A (ja) 2020-03-02 2023-04-19 プロジェニア インコーポレイテッド 病原菌外壁成分基盤の生病原体模倣ナノ粒子及びその製造方法
WO2022031057A1 (ko) 2020-08-04 2022-02-10 성균관대학교산학협력단 활성화 부위가 일시적으로 비활성화된 톨-유사 수용체 7 또는 8 작용자와 기능성 약물의 결합체 및 그 용도
US20230355750A1 (en) 2020-08-04 2023-11-09 Progeneer Inc. Kinetically acting adjuvant ensemble
EP4194006A4 (en) 2020-08-04 2024-12-04 Progeneer Inc. mRNA VACCINE WITH AN ADJUVANT CAPABLE OF KINETIC CONTROL

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5476659A (en) 1982-11-09 1995-12-19 The Scripps Research Institute Cancerous B cell treatment using substituted nucleoside derivatives
US5166141A (en) 1983-11-01 1992-11-24 Scripps Clinic And Research Foundation Immunostimulating 7-deaza-7-oxa- and 7-deaza-7-oxo-analogs of 8-substituted-guanine-9-(1'-beta-D-aldoglycosidyl) derivatives and methods of treating test animals
US5041426A (en) 1987-12-21 1991-08-20 Brigham Young University Immune system enhancing 3-β-d-ribofuranosylthiazolo[4,5-d]pyridimine nucleosides and nucleotides
US5248776A (en) * 1990-12-05 1993-09-28 University Of Georgia Research Foundation, Inc. Process for enantiomerically pure β-L-1,3-oxathiolane nucleosides
EP1072607A3 (en) 1996-10-16 2001-09-12 ICN Pharmaceuticals, Inc. Purine L-nucleosides, analogs and uses therof
DE69729887T2 (de) 1996-10-16 2005-07-28 ICN Pharmaceuticals, Inc., Costa Mesa Purin-L-Nukleoside, Analoga und deren Verwendung
EP1124562B1 (en) * 1998-11-02 2005-01-19 Gilead Sciences, Inc. Combination therapy to treat hepatitis b virus
CA2426187C (en) * 2000-10-18 2011-08-16 Pharmasset Limited Modified nucleosides for the treatment of viral infections and abnormal cellular proliferation
AU2002329970A1 (en) * 2001-09-04 2003-03-18 Isis Pharmaceuticals, Inc. Pyrrolo(2,3-d)pyrimidines for inhibiting rna-dependent rna viral polymerase
US20050004144A1 (en) 2003-04-14 2005-01-06 Regents Of The University Of California Combined use of IMPDH inhibitors with toll-like receptor agonists
NZ545536A (en) 2003-09-05 2010-04-30 Anadys Pharmaceuticals Inc TLR7 ligands for the treatment of hepatitis C
DK1824482T3 (en) 2004-12-17 2014-03-24 Anadys Pharmaceuticals Inc AND 3,5-disubstituted 3,5,7-trisubstituted-3H-oxazolo AND 3H-thiazolo [4,5-d] pyrimidin-2-one compounds and prodrugs thereof
CN101212968B (zh) * 2004-12-17 2011-11-16 安那迪斯药品股份有限公司 3,5-二取代的和3,5,7-三取代的-3H-噁唑并以及3H-噻唑并[4,5-d]嘧啶-2-酮化合物及其前药
AR053347A1 (es) * 2005-04-06 2007-05-02 Astrazeneca Ab Derivados de [1,3]tiazolo[4,5-d]pirimidin-2(3h)-ona 5,7-sustituidos
AR061024A1 (es) 2006-05-22 2008-07-30 Novartis Ag Maleato de 5-amino-3- (2'3'-di-o-acetil-beta-d-ribofuranosil)-3h-tiazolo[4,5-d] pirimidin-2-ona.
JP5345527B2 (ja) 2006-06-22 2013-11-20 アナディス ファーマシューティカルズ インク プロドラッグである５−アミノ−３−（３’−デオキシ−β−Ｄ−リボフラノシル）−チアゾロ［４，５−ｄ］ピリミジン−２，７−ジオン
JP5225991B2 (ja) 2006-07-18 2013-07-03 アナディス ファーマシューティカルズ インク チアゾロ［４，５−ｄ］ピリミジンのカーボネート及びカルバメートプロドラッグ
BRPI0717741A2 (pt) 2006-10-17 2014-04-08 Anadys Pharmaceuticals Inc Compostos e respectivos método de preparação, método de redução de composto de sulfonil substituído, composição farmacêutica método de tratamento ou prevenção de doença
WO2009026292A1 (en) 2007-08-20 2009-02-26 Anadys Pharmaceuticals, Inc. Dosing methods for treating disease
UA111640C2 (uk) * 2011-11-08 2016-05-25 Ф. Хоффманн-Ля Рош Аг ПОХІДНІ [1,2,3]ТРИАЗОЛО[4,5-d]ПІРИМІДИНУ ЯК АГОНІСТИ КАНАБІНОЇДНОГО РЕЦЕПТОРА 2
CN104230952B (zh) * 2014-08-16 2017-02-01 沈阳药科大学 含有嘧啶骨架的化合物及其制备方法和用途
EP3204392A1 (en) * 2014-10-11 2017-08-16 F. Hoffmann-La Roche AG Compounds for use in the treatment of infectious diseases

Also Published As

Publication number Publication date
US10183954B2 (en) 2019-01-22
CN107743491A (zh) 2018-02-27
WO2016180691A1 (en) 2016-11-17
HK1250709A1 (zh) 2019-01-11
US20180065991A1 (en) 2018-03-08
JP2018515503A (ja) 2018-06-14
EP3294745A1 (en) 2018-03-21
CN107743491B (zh) 2020-08-21
EP3294745B1 (en) 2020-01-01

Similar Documents

Publication Publication Date Title
JP6806709B2 (ja) ウイルス感染症の治療と予防のための新規置換アミノチアゾロピリミジンジオン
US10975098B2 (en) Substituted aminothiazolopyrimidinediones for the treatment of virus infection
JP6568106B2 (ja) Ｂ型肝炎ウイルス感染症の治療及び予防のための新規ジヒドロキノリジノン類
JP6553825B2 (ja) 抗がん剤として有用な置換カルボヌクレオシド誘導体
JP6817217B2 (ja) ウイルス感染症の治療および予防のための３−置換された５−アミノ−６Ｈ−チアゾロ［４，５−ｄ］ピリミジン−２，７−ジオン化合物
TWI840646B (zh) 作為jak抑制劑之聯吡唑衍生物
EP2855476B1 (en) Tetrahydropyrazolopyrimidine compounds
JP2021191764A (ja) ジアゼピノン誘導体及びｂ型肝炎感染症の治療におけるその使用
JP6779232B2 (ja) ウイルス感染の治療又は予防のための新規オキサチオランカルボン酸と誘導体
JP2020528062A (ja) ピペラジンヘテロアリール誘導体、その製造方法、およびその医薬での使用
JP2018514575A (ja) Ｂ型肝炎ウイルス感染症の治療用のＨＢｓＡｇ（ＨＢＶ表面抗原）及びＨＢＶ ＤＮＡ産生の阻害剤としてのテトラヒドロピリドピリミジン類及びテトラヒドロピリドピリジン類
KR20170113658A (ko) Tlr7 작용제 및 hbv 캡시드 조립 억제제를 사용하는 병용 치료
JP2017531655A (ja) 感染性疾患の処置に使用するための化合物
TW202321246A (zh) Prmt5抑制劑
JP2023536891A (ja) 重症肺炎を治療するためのｊａｋ阻害剤化合物
KR20100136469A (ko) 피롤로피리미딘카르복시아미드
CN102574861A (zh) 甲基吡咯并嘧啶甲酰胺
HK1250709B (zh) 用於治疗和预防病毒感染的新的氧硫杂环戊烷甲酸及其衍生物
JP7328977B2 (ja) ウイルス感染の処置および予防のための新規のスルホン化合物および誘導体
HK1248711B (zh) 用於治疗和预防病毒感染的新的取代的氨基噻唑并嘧啶二酮
HK1251554B (zh) 用於治疗和预防病毒感染的取代的氨基噻唑并嘧啶二酮

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190426

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190426

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200213

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20200213

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200508

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200804

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200916

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20201013

R150 Certificate of patent or registration of utility model

Ref document number: 6779232

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees